RxSight (RXST) Asset Writedowns and Impairment (2020 - 2026)
RxSight (RXST) posted Asset Writedowns and Impairment of $60000.0 for Q1 2026, down 90.26% on a QoQ basis from $616000.0 in Q4 2025, and up 93.55% year-over-year from $31000.0 in Q1 2025.
RxSight (RXST) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
RxSight's Asset Writedowns and Impairment history runs 7 years deep, the most recent figure standing at $60000.0 for Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 93.55% year-over-year to $60000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 505.25% YoY) and the FY2025 annual result came in at $1.9 million, up 378.22% from the prior year.
- Asset Writedowns and Impairment was $60000.0 for Q1 2026 at RxSight, down from $616000.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.2 million in Q2 2025 and bottomed at -$1000.0 in Q3 2023.
- A 5-year average of $194823.5 and a median of $71000.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2023 — Asset Writedowns and Impairment plunged 100.3% — and 2024, when it surged 16700.0%.
- RxSight's Asset Writedowns and Impairment stood at $298000.0 in 2022, then plunged by 49.33% to $151000.0 in 2023, then plunged by 52.98% to $71000.0 in 2024, then soared by 767.61% to $616000.0 in 2025, then plunged by 90.26% to $60000.0 in 2026.
- Business Quant data shows RXST's Asset Writedowns and Impairment at $60000.0 in Q1 2026, $616000.0 in Q4 2025, and $66000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.27 Bn | 175.98 Bn | 6.27 Bn |
| 2 | Stryker | 128.81 Bn | 125.93 Bn | 3.81 Bn |
| 3 | Medtronic | 108.63 Bn | 99.41 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.42 Bn | 66.96 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.51 Bn | 44.84 Bn | 1.29 Bn |
| 6 | Dexcom | 28.39 Bn | 27.27 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.31 Bn | 26.03 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.93 Bn | 26.35 Bn | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.35 Bn | 2.07 Bn |
| 10 | RxSight | 227.39 Mn | -190.82 Mn | 23.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60,000.00 |
| Mar 31, 2026 | 60,000.00 |
| Dec 31, 2025 | 616,000.00 |
| Dec 31, 2025 | 616,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Sep 30, 2025 | 66,000.00 |
| Jun 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 31,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Dec 31, 2024 | 71,000.00 |
| Sep 30, 2024 | 166,000.00 |
| Sep 30, 2024 | 166,000.00 |
| Jun 30, 2024 | 56,000.00 |
| Jun 30, 2024 | 56,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Mar 31, 2024 | 111,000.00 |
| Dec 31, 2023 | 151,000.00 |
| Dec 31, 2023 | 151,000.00 |